Background: Although protocol registration of systematic reviews/meta-analysis (SR/MA) is still not mandatory, it is highly recommended that authors publish their SR/MA protocols prior to submitting their manuscripts for publication as recommended by the Cochrane guidelines for conducting SR/MAs. our aim was to assess the awareness, obstacles, and opinions of SR/MA authors about the protocol registration process. Methods: A cross-sectional survey study included the authors who published SR/MAs during the period from 2010 to 2016, and they were contacted for participation in our survey study. They were identified through the literature search of SR/MAs in Scopus database. An online questionnaire was sent to each participant via e-mail after receiving their approval to join the study. We have sent 6650 emails and received 275 responses. Results: A total of 270 authors responses were complete and included in the final analysis. Our results has shown that PROSPERO was the most common database used for protocol registration (71.3%). The registration-to-acceptance time interval in PROSPERO was less than 1 month (99.1%). Almost half of the authors (44.2%) did not register their protocols prior to publishing their SR/MAs and according to their opinion that the other authors lack knowledge of protocol importance and mandance to be registered, was the most commonly reported reason (44.9%). A significant percenatge of respondents (37.4%) believed that people would steal their ideas from protocol databases, while only 5.3% reported that their SR/MA had been stolen. However, the majority (72.9%) of participants have agreed that protocol registries play a role in preventing unnecessary duplication of reviews. Finally, 37.4% of participants agree that SR/MA protocol registration should be mandatory.

No abstract

緒 言 Despite significant advances in the prevention and treatment of malaria, it remains to be one of the calamitous global health and socioeconomic concern. Several drugs are currently available for malaria treatment, however parasites began to develop resistance against most of these drugs including the first line drug, Artemisinin. A newly approved vaccine, RTS, S, has raised hope for preventive therapy, yet suffered with limited efficacy (shorter and stage-specific immunity). As a result, look for new small molecule drug candidates with novel target/mechanism of action has become pivotal. There are various phenotypic screening methods to identify novel antimalarials, however, most of them are time-consuming, costly and laborious. In contrary, in silico approach found to be effective to screen millions of compounds comparatively at shorter time and less expensive way than conventional screening. Therefore, in this study, we developed new prediction models for in silico antimalarial compound screening based on the physicochemical properties of small chemical compounds (hemozoin inhibitors) identified from our previous study. 対象と方法In this study, 224 positive hemozoin inhibitors (obtained from our previous study), were tested for in vitro erythrocytic antimalarial activity against chloroquine -mefloquine sensitive Plasmodium falciparum strain, 3D7A and their antihemozoin activity. The physicochemical properties of the active compounds (antimalarials and hemozoin inhibitors) were extracted from ChemSpider and SciFinder databases. To develop the model, univariable logistic regression was performed to examine the association between physicochemical properties (variables) and antimalarial activity of the compounds (outcome). Subsequently, to find independent predictors, variables P<0.1 and/or significant variables in previous study, were subjected to multivariable analysis using Bayesian model averaging (BMA) based on the Bayesian information criterion (BIC), where the smaller BIC value indicates the better model. The data were randomly divided into two sets -training and testing, with a ratio of 70:30. The BMA models were developed using training set and validated by testing data set. The data were analysed by using RStudio 1.0.44